The co-operative research and development agreement, initiated in March 2006, was extended through September 2009.
John Kovach, president and CEO of Lixte, said: “The scientific interaction with the research team at the molecular pathogenesis unit, surgical neurology branch, National Institute of Neurological Disorders and Stroke (NINDS), has been highly productive and is a good example of how government and private sector scientific organizations may accelerate the drug development process.”